Abbisko Cayman Limited (HK:2256) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbisko Cayman Limited has announced promising results from a phase I clinical trial of its drug irpagratinib, which showed significant efficacy in treating advanced hepatocellular carcinoma with FGF19 overexpression, achieving a 44.8% overall response rate. Additionally, the company released the design for a phase II study of another drug, pimicotinib, for advanced pancreatic cancer treatment. Investors are cautioned as the drugs are still pending market approval.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.